Hyloris Pharmaceuticals (HYL) H1 2024 earnings summary

Executive summary

• Revenue for H1 2024 rose to €4.15 million, mainly from milestone payments and royalties, up from €0.61 million in H1 2023, reflecting the first US launch of Maxigesic IV and increased sales-based royalties.

• Net loss narrowed to €3.49 million from €5.62 million year-over-year, driven by higher revenue and lower R&D expenses.

• Cash and cash equivalents stood at €27.4 million at June 30, 2024, down from €30.4 million at year-end 2023, with a net cash outflow from operations of €3.35 million.

• The company operates as a single segment focused on specialty pharmaceuticals, with three commercialized products and a broad pipeline.

Financial highlights

• Revenue increased to €4.15 million in H1 2024 from €0.61 million in H1 2023, mainly due to milestone and royalty income.

• Operating loss (EBIT) improved to €3.98 million from €6.10 million year-over-year.

• R&D expenses decreased by 8% to €5.31 million, while general and administrative expenses rose 27% to €3.15 million, mainly due to litigation costs.

• Basic and diluted loss per share was €0.12, compared to €0.20 in H1 2023.

• Cash and cash equivalents decreased by €3.0 million during H1 2024, ending at €27.4 million.

Outlook and guidance

• The Board considers the company a going concern, supported by its cash position and expected milestone payments, but notes that additional funding may be needed for US commercialization of cardiology products.

• R&D expenses are expected to increase in H2 2024 due to project phasing.

• The company may seek partnerships, capital raises, or loans to fund future commercialization efforts.